Cas:313337-32-5 6-Fluoro-7-methyl-1H-indole manufacturer & supplier

We serve Chemical Name:6-Fluoro-7-methyl-1H-indole CAS:313337-32-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

6-Fluoro-7-methyl-1H-indole

Chemical Name:6-Fluoro-7-methyl-1H-indole
CAS.NO:313337-32-5
Synonyms:4-Fluoro-7-methyl Indole;6-Fluoro-7-methyl-1H-indole;1H-Indole, 4-fluoro-7-methyl-;1H-Indole, 6-fluoro-7-methyl-;4-Fluoro-7-methyl-1H-indole
Molecular Formula:C9H8FN
Molecular Weight:149.165
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:265.8±20.0 °C at 760 mmHg
Density:1.2±0.1 g/cm3
Index of Refraction:1.627
PSA:15.79000
Exact Mass:149.064072
LogP:2.65

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 4-Fluoro-7-methyl Indole chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Fluoro-7-methyl-1H-indole physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4-Fluoro-7-methyl Indole Use and application,4-Fluoro-7-methyl-1H-indole technical grade,usp/ep/jp grade.


Related News: As we expand our offering into the US and beyond, NOVA aims to become the go-to partner for pharma and biotech companies for in silico clinical trial support. I am delighted to welcome Grégoire to the Novadiscovery team and look forward to working closely with him.” UNII:2ZAD6VMP77 manufacturers The outlay will be used to grow Takeda’s portfolio of treatments and boost capacity to manufacture additional products for the rare disease community, Stephen Hatke, Takeda’s Thousand Oaks site head, said in a YouTube video about the expansion. The company didn’t name the specific products it plans to make there. 2-amino-4-phenylbut-3-enoic acid suppliers Mene Pangalos, executive vice president, BioPharmaceuticals R&D, said: “The data being presented at EULAR add to the growing body of evidence for anifrolumab that demonstrate a compelling clinical profile with the potential to address significant unmet medical needs in this debilitating disease. UNII:OUT5YHB7BO vendor & factory.